USyd Team Immunotherapeutics

This project will develop novel bispecific immunetherapeutics for different kinds of cancers.

We will use monoclonal antibodies (mAbs) to form bispecifics, which will be able to simultaneously engage with immune cells and tumour cells. In addition to cancer, our bispecifics system can be used as a platform for the development of next generation targeted immunotherapeutics for a wide range of applications including autoimmune disorders.